The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104).
 
Yi-Long Wu
Honoraria - AstraZeneca; Lilly; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck; Roche
Research Funding - Boehringer Ingelheim (Inst); Roche (Inst)
 
Wenzhao Zhong
No Relationships to Disclose
 
Qun Wang
No Relationships to Disclose
 
Song-Tao Xu
No Relationships to Disclose
 
Wei-Min Mao
No Relationships to Disclose
 
Lin Wu
No Relationships to Disclose
 
Yi Shen
No Relationships to Disclose
 
Yong-Yu Liu
No Relationships to Disclose
 
Chun Chen
No Relationships to Disclose
 
Ying Cheng
No Relationships to Disclose
 
Lin Xu
No Relationships to Disclose
 
Jun Wang
No Relationships to Disclose
 
Ke Fei
No Relationships to Disclose
 
Xiao-Fei Li
No Relationships to Disclose
 
Jian Li
No Relationships to Disclose
 
Cheng Huang
No Relationships to Disclose
 
Zhi-Dong Liu
No Relationships to Disclose
 
Ke-Neng Chen
No Relationships to Disclose
 
Hong-Hong Yan
No Relationships to Disclose
 
Xue-Ning Yang
No Relationships to Disclose